BRAF Genetic Alteration Cell Line Panel Item ID: ATCTCP1032

View Permits

This validated panel is composed of 8 select human tumor cell lines carrying BRAF mutations, and is useful for BRAF pathway research and for anti-cancer drug discovery.

Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country.

BRAF gene is a proto-oncogene encoding the BRAF protein, a serine/threonine kinase of the RAF family that acts downstream of RAS and upstream of MEK in the MAPK/ERK signaling pathway. BRAF mediates cell division, proliferation, and differentiation in response to a host of stimuli.  Mutations in BRAF lead to excessive cellular proliferation and enhanced survival, and often underlie birth defects, and cancers of the thyroid and skin.  The BRAF gene is most frequently mutated at codon 600.  BRAF V600E mutation has been found in more than 60% of melanomas, as well as 7-8% of other cancers. The BRAF Genetic Alteration Cell Panel (ATCC TCP-1032) is composed of eight selected human tumor cell lines from various common cancer types that carry BRAF hotspot mutations in codon 600.  The BRAF mutation status of each cell line has been sequenced and validated by ATCC.  This panel is useful for BRAF pathway research and BRAF inhibitors anti-cancer drug discovery.